Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ARGX argenex	$577.92 +3.9%	$564.45	$457.42 ▼ $678.21	$35.37B	0.37	333,538 shs	464,676 shs
BNTX BioNTech	$112.49 +1.7%	$104.07	$76.53 ▼ $131.49	$26.60B	1.29	942,979 shs	786,508 shs
DHR Danaher	$193.40 +0.3%	$196.11	$171.00 ▼ $281.70	$138.41B	0.77	3.52 million shs	2.66 million shs
QGEN Qiagen	$48.32 +1.8%	$45.70	$37.63 ▼ $49.30	$10.74B	0.68	1.22 million shs	1.24 million shs

Investing Strategies To Help Grow Your Retirement Income

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ARGX argenex	-0.95%	+3.22%	-3.79%	-5.38%	+20.35%
BNTX BioNTech	-0.32%	-0.90%	+3.83%	+12.62%	+31.34%
DHR Danaher	-2.50%	-3.97%	-3.88%	+0.99%	-21.72%
QGEN Qiagen	-1.70%	-0.85%	+0.76%	+14.51%	+16.72%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ARGX argenex	4.3899 of 5 stars	4.5	3.0	0.0	0.0	3.4	1.7	2.5
BNTX BioNTech	1.638 of 5 stars	3.4	2.0	0.0	0.0	2.2	0.8	0.0
DHR Danaher	4.9663 of 5 stars	4.4	3.0	1.7	4.3	4.1	3.3	1.3
QGEN Qiagen	3.6956 of 5 stars	1.2	4.0	1.7	4.5	2.3	1.7	1.3

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ARGX argenex	3.10	Buy	$728.06	25.98% Upside
BNTX BioNTech	2.83	Moderate Buy	$136.58	21.42% Upside
DHR Danaher	2.85	Moderate Buy	$248.43	28.45% Upside
QGEN Qiagen	2.30	Hold	$49.40	2.25% Upside

Current Analyst Ratings Breakdown

Latest QGEN, DHR, ARGX, and BNTX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/16/2025	BNTX BioNTech	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$127.00 ➝ $126.00
7/11/2025	DHR Danaher	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Sector Perform ➝ Sector Outperform	$275.00
7/10/2025	BNTX BioNTech	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Overweight ➝ Overweight	$132.00 ➝ $133.00
7/8/2025	ARGX argenex	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold ➝ Buy
7/8/2025	DHR Danaher	Evercore ISI Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$230.00 ➝ $226.00
7/3/2025	ARGX argenex	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$700.00
7/1/2025	ARGX argenex	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$720.00
6/26/2025	QGEN Qiagen	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$50.00 ➝ $53.00
6/25/2025	BNTX BioNTech	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$138.00
6/24/2025	ARGX argenex	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$715.00
6/24/2025	DHR Danaher	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$215.00 ➝ $225.00

(Data available from 7/16/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ARGX argenex	$2.58B	13.71	$3.06 per share	188.95	$90.49 per share	6.39
BNTX BioNTech	$2.75B	9.85	N/A	N/A	$87.61 per share	1.28
DHR Danaher	$23.82B	5.81	$10.69 per share	18.10	$68.60 per share	2.82
QGEN Qiagen	$2.00B	5.36	$3.21 per share	15.06	$16.05 per share	3.01

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ARGX argenex	$833.04M	$16.21	35.65	53.26	1.03	40.20%	16.15%	14.33%	7/24/2025 (Estimated)
BNTX BioNTech	-$719.92M	-$3.40	N/A	N/A	N/A	-27.37%	-3.94%	-3.41%	8/4/2025 (Estimated)
DHR Danaher	$3.90B	$5.15	37.55	22.57	2.78	15.81%	10.80%	6.89%	7/22/2025 (Estimated)
QGEN Qiagen	$83.59M	$0.40	121.14	19.64	2.45	4.68%	14.61%	8.80%	8/5/2025 (Estimated)

Latest QGEN, DHR, ARGX, and BNTX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/5/2025	Q2 2025	QGEN Qiagen	$0.60	N/A	N/A	N/A	$523.97 million	N/A
8/4/2025	Q2 2025	BNTX BioNTech	-$1.38	N/A	N/A	N/A	$161.26 million	N/A
7/24/2025	Q2 2025	ARGX argenex	$2.87	N/A	N/A	N/A	$776.82 million	N/A
7/22/2025	Q2 2025	DHR Danaher	$1.64	N/A	N/A	N/A	$5.83 billion	N/A
5/8/2025	Q1 2025	ARGX argenex	$2.32	$2.58	+$0.26	$2.58	$748.34 million	$1.35 billion
5/7/2025	Q1 2025	QGEN Qiagen	$0.50	$0.55	+$0.05	$0.41	$465.66 million	$483.46 million
4/22/2025	Q1 2025	DHR Danaher	$1.62	$1.88	+$0.26	$1.32	$5.58 billion	$5.74 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ARGX argenex	N/A	N/A	N/A	N/A	N/A
BNTX BioNTech	$1.53	1.36%	N/A	N/A	N/A
DHR Danaher	$1.28	0.66%	N/A	24.85%	2 Years
QGEN Qiagen	$0.25	0.52%	N/A	62.50%	N/A

Latest QGEN, DHR, ARGX, and BNTX Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
5/6/2025	DHR Danaher	quarterly	$0.32	0.67%		6/27/2025	7/25/2025
7/1/2025	QGEN Qiagen		$0.25	0.52%	7/2/2025	7/3/2025	7/10/2025

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ARGX argenex	N/A	7.29	6.68
BNTX BioNTech	0.01	10.18	10.02
DHR Danaher	0.31	1.43	1.05
QGEN Qiagen	0.40	3.37	2.83

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ARGX argenex	60.32%
BNTX BioNTech	15.52%
DHR Danaher	79.05%
QGEN Qiagen	70.00%

Insider Ownership

Company	Insider Ownership
ARGX argenex	2.43%
BNTX BioNTech	19.20%
DHR Danaher	11.20%
QGEN Qiagen	9.00%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ARGX argenex	1,599	61.20 million	59.71 million	Optionable
BNTX BioNTech	6,772	240.39 million	194.24 million	Optionable
DHR Danaher	63,000	715.67 million	635.52 million	Optionable
QGEN Qiagen	5,765	222.29 million	202.29 million	Optionable

QGEN, DHR, ARGX, and BNTX Headlines

Recent News About These Companies

Bank of New York Mellon Corp Sells 41,846 Shares of Qiagen N.V. (NYSE:QGEN)

July 15 at 3:35 AM | marketbeat.com

Massachusetts Financial Services Co. MA Has $1.02 Billion Holdings in Qiagen N.V. (NYSE:QGEN)

July 14 at 9:10 AM | marketbeat.com

QGEN or EXAS: Which Is the Better Value Stock Right Now?

July 10, 2025 | zacks.com

Qiagen N.V. (NYSE:QGEN) Shares Bought by Banque Pictet & Cie SA

July 10, 2025 | marketbeat.com

Beverly Hills Private Wealth LLC Invests $299,000 in Qiagen N.V. (NYSE:QGEN)

July 8, 2025 | marketbeat.com

QIAGEN N.V. to Release Results for Q2 2025 and Hold Webcast

July 8, 2025 | businesswire.com

Analysts Set QIAGEN N.V. (NYSE:QGEN) Target Price at $49.40

July 6, 2025 | americanbankingnews.com

Qiagen Teams With Gencurix to Expand Digital PCR Cancer Assays

July 3, 2025 | msn.com

Qiagen N.V. (NYSE:QGEN) Receives Average Recommendation of "Hold" from Analysts

July 3, 2025 | marketbeat.com

Qiagen N.V. (NYSE:QGEN) Declares Dividend of $0.25

July 1, 2025 | marketbeat.com

Allspring Global Investments Holdings LLC Raises Holdings in QIAGEN N.V. (NYSE:QGEN)

June 29, 2025 | marketbeat.com

Qiagen Partnership Program Aims to Build out Clinical dPCR Menu

June 27, 2025 | 360dx.com3

Qiagen N.V. (QGEN) Stock Price, Quote, News & Analysis - Seeking Alpha

June 27, 2025 | seekingalpha.com

Canvas Wealth Advisors LLC Trims Position in Qiagen N.V. (NYSE:QGEN)

June 27, 2025 | marketbeat.com

Here's Why Qiagen (QGEN) is a Strong Value Stock - Nasdaq

June 26, 2025 | nasdaq.com

Qiagen (NYSE:QGEN) Price Target Raised to $53.00 at Bank of America

June 26, 2025 | marketbeat.com

QIAGEN Announces Election of Stephen Rusckowski as Chairman of Supervisory Board

June 26, 2025 | businesswire.com

Barclays Initiates Coverage of Qiagen N.V. (QGEN) with Overweight Recommendation

June 25, 2025 | msn.com

Bank of Italy Has $31.72 Million Stock Position in Qiagen N.V. (NYSE:QGEN)

June 25, 2025 | marketbeat.com

Barclay's Initiates Coverage of Qiagen With Overweight Rating

June 24, 2025 | 360dx.com3

QGEN vs. EXAS: Which Stock Is the Better Value Option?

June 24, 2025 | zacks.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

QGEN, DHR, ARGX, and BNTX Company Descriptions

argenex NASDAQ:ARGX

$577.92 +21.96 (+3.95%)

Closing price 04:00 PM Eastern

Extended Trading

$577.80 -0.12 (-0.02%)

As of 06:45 PM Eastern

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren's syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis. The company is developing ARGX-213 targets FcRn; ARGX-121 and ARGX-220 targets immune system; ARGX-109 targets IL-6; ARGX-118 for inflammation; and ARGX-109, as well as cusatuzumab, ARGX-112, ARGX-114, and ARGX-115. It owns VYVGART; VYVGART HYTRULO; VYVDURA; ARGENX; ABDEG; NHANCE; SIMPLE ANTIBODY; and ARGENXMEDHUB. The company has strategic partnership with AbbVie S.À.R.L., Zai Lab Limited, and LEO Pharma A/S; and collaboration and license agreement with Genor Biopharma Co. Ltd, Université Catholique de Louvain, Sopartec S.A., NYU Langone Health, Leiden University Medical Center, AgomAb Therapeutics NV, Broteio Pharma B.V., VIB vzw, University of Texas, BioWa, Inc., and Shire International GmbH. It has collaboration agreement with Genmab A/S to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology, as well as a strategic collaboration with IQVIA Holdings Inc. to provide safety systems and services. argenx SE was incorporated in 2008 and is based in Amsterdam, the Netherlands.

BioNTech NASDAQ:BNTX

$112.49 +1.84 (+1.66%)

Closing price 04:00 PM Eastern

Extended Trading

$112.19 -0.30 (-0.27%)

As of 07:41 PM Eastern

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer. It develops BNT122, which is in Phase II clinical trial for first-line melanoma and in Phase I clinical trial to treat multiple solid tumors; BNT131 that is in Phase I clinical trial for multiple solid tumors; BNT141 and BNT142 that are in Phase I clinical trial to treat multiple solid tumors; BNT151, BNT152, and BNT153 to treat solid tumors; BNT211 to treat multiple solid tumors, and BNT221 for pancreatic and other cancers; BNT311 which are in Phase II clinical trial to treat metastatic non-small cell lung cancer and Phase I/II clinical trial to treat multiple solid tumors; and BNT312, which is in Phase 2 clinical trial to treat multiple solid tumors, as well as ONC-392, which is in Phase III clinical trial to treat ovarian cancer and Phase I/II clinical trial to treat multiple solid tumors. It develops BNT321, an IgG1 monoclonal antibody in Phase I clinical trial for pancreatic cancer; BNT411, a small molecule immunomodulator product candidate in Phase I clinical trial for solid tumors; BNT322, which is in Phase I/Ib clinical trial for multiple solid tumors; and prophylactic vaccine for shingles, malaria, tuberculosis, HSV-2, and other infectious diseases. It has collaborations with Genentech, Inc.; Sanofi S.A.; Genmab A/S; Pfizer Inc.; Shanghai Fosun Pharmaceutical (Group) Co., Ltd; and Ryvu Therapeutics S.A. BioNTech SE was incorporated in 2008 and is based in Mainz, Germany.

Danaher NYSE:DHR

$193.40 +0.54 (+0.28%)

Closing price 03:59 PM Eastern

Extended Trading

$193.84 +0.44 (+0.23%)

As of 07:25 PM Eastern

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions. The Life Sciences segment provides mass spectrometers; flow cytometry, genomics, lab automation, centrifugation, liquid handling automation instruments, antibodies and reagents, and particle counting and characterization; microscopes; protein consumables; industrial filtration products; and genomic medicines, such as custom nucleic acid products, plasmid DNA, RNA, and proteins under the ABCAM, ALDEVRON, BECKMAN COULTER, IDT, LEICA MICROSYSTEMS, MOLECULAR DEVICES, PALL, PHENOMENEX and SCIEX brands. The Diagnostics segment offers chemistry, immunoassay, microbiology, and automation systems; and molecular, acute care, and pathology diagnostics products. This segment also provides clinical instruments, reagents, consumables, software, and services for hospitals, physicians' offices, reference laboratories, and other critical care settings. The company was formerly known as Diversified Mortgage Investors, Inc. and changed its name to Danaher Corporation in 1984. Danaher Corporation was founded in 1969 and is based in Washington, the District of Columbia.

Qiagen NYSE:QGEN

$48.32 +0.87 (+1.82%)

Closing price 03:59 PM Eastern

Extended Trading

$48.32 0.00 (0.00%)

As of 04:48 PM Eastern

QIAGEN NV is a holding company, which engages in the provision of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. The company sample technologies isolate and process DNA, RNA, and proteins from blood, tissue, and other materials. The firm assay technologies make these biomolecules visible and ready for analysis. Its bioinformatics software and knowledge bases interpret data to report relevant, actionable insights. The company was founded by Detlev H. Riesner and Metin Colpan on April 29, 1996, and is headquartered in Venlo, the Netherlands.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time